Electra Therapeutics, Inc. (ETRA) company profile
Close on Nov 17, 2026Market cap $524.94MP/E –Yield –
About Electra Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Electra Therapeutics, Inc. is listed on Nasdaq under the ticker ETRA, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Electra Therapeutics, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 230 East Grand Avenue, Suite S-100 94080
- Phone
- (888) 743-2290
- Website
- electra-therapeutics.com
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- ETRA
- Exchange
- Nasdaq
- IPO date
- Sep 18, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2088082
- CUSIP
- 284825106
- ISIN
- US2848251060
- FIGI
- BBG012QDV1C7
- Share class FIGI
- BBG012QDV1D6
- EIN
- 83-2193635
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Quehuong (Kathy) Dong | President & CEO, Director | 455,484 |
| Gary S. Koe | Chief Technical Officer | 63,656 |
| Graham Parry | Chief Scientific Officer | 85,504 |
| David J. Tucker | Principal Accounting Officer | – |
| Christopher William Clark | Chief Financial Officer | – |
| Kim-Hien Dao | Chief Medical Officer | – |
| Carl L. Gordon | Director | 2,194,579 |
| Genesis GP LLC OrbiMed | Director | – |
| Capital GP VII LLC OrbiMed | Director | 5,126,891 |
| Advisors Llc Orbimed | Director | 2,194,579 |
| Nancy Stagliano | Director | 255,635 |
| Matthew K. Fust | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 18, 2026
- Offer price
- $15.00
- Securities offered
- 23,333,334
- Gross proceeds
- $350.00M
- Exchange
- Nasdaq
- First trading day
- Sep 18, 2026
- First-day close
- $13.25-11.7%
- Lock-up ends (est.)
- Mar 17, 2027
“The initial public offering price is $15.00 per share of our common stock.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 18, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 18, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?